(HealthDay News) — The incidence of cardiac outcomes remains low in long-term follow-up of patients who received adjuvant trastuzumab for early-stage breast cancer, according to a study published online in the Journal of Clinical Oncology.
Evandro de Azambuja, MD, PhD, from the Jules Bordet Institute in Brussels, and colleagues assessed 8-year median follow-up data among participants in the Herceptin Adjuvant study. Human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer patients had been randomly assigned to 2 years of trastuzumab (1,673 patients), 1 year of trastuzumab (1,682 patients), or observation (1,744 patients).
The researchers found that adverse cardiac events leading to discontinuation of trastuzumab occurred in 9.4% of patients in the 2-year arm and 5.2% of patients in the 1-year arm.
RELATED: Trastuzumab Ups Cardiac Risk for Older Women With Breast Cancer
All three arms had low levels of cardiac death, severe congestive heart failure (CHF; incidence 0.8%, 0.8%, and 0.0%, respectively), and confirmed significant left ventricular ejection fraction (LVEF) decrease (7.2%, 4.1%, and 0.9%, respectively), but the incidence of severe CHF and confirmed significant LVEF decrease was significantly higher in the 2-year and 1-year trastuzumab arms versus the observation arm.
“Long-term assessment at eight-year median follow-up confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy, and cardiac events were reversible in the vast majority of patients,” concluded the authors.
Several authors disclosed financial ties to the pharmaceutical industry.